Harnessing durable immunity to maintain remission — and to intercept hematologic malignancies before symptomatic transition.
An off-the-shelf, cell-based immunotherapy that presents a comprehensive antigenic blueprint of multiple myeloma to the patient’s own immune system — built from two human myeloma cell lines together with GM-CSF–secreting cells that act as a built-in immune adjuvant.
HLA-agnostic and allogeneic — manufactured in advance, with no patient-specific tissue matching required.
Presents a wide antigen array rather than a single marker, reducing the opportunity for tumor escape.
GM-CSF recruits antigen-presenting cells to generate long-lived, marrow-homing memory T cells.
BCMA · FGFR3 · SLAMF7
MAGE-A3 · NY-ESO-1
TP53 · NRAS · BRAF
A broad myeloma antigen array is delivered with a GM-CSF adjuvant.
GM-CSF attracts antigen-presenting cells to prime the response.
De novo expansion of durable, marrow-homing memory T-cell clones.
Permanent, multi-target surveillance that maintains remission.
Maintains remission rather than simply reducing tumor burden — while avoiding the toxicities of passive antibody therapies.
Single-arm study at Johns Hopkins. No treatment-related dose-limiting toxicities; immune responses persisting up to 5–7 years; progression-free survival not reached at extended follow-up.
A randomized Phase II study of MyeliMMune™ for smoldering myeloma patients.
A randomized confirmatory trial to follow positive Phase II proof-of-concept, targeting FDA approval for this first-in-class therapy.
Meridian Therapeutics is a clinical-stage biopharmaceutical company developing immune-based therapies for hematologic malignancies, with an initial focus on multiple myeloma. We exclusively own the MyeliMMune™ intellectual property and existing cGMP-manufactured inventory, with a corporate IND in place.
Intercept myeloma before symptomatic disease takes hold — using the durability of the immune system to maintain and extend the responses that conventional therapies achieve but rarely sustain.
Intercept hematologic malignancies before symptomatic transition, applying the same active-immunity approach across blood cancers beyond multiple myeloma.
Venture investor and author of Nail It Then Scale It; 150+ company investments.
Serial deep-tech founder; former VP of Technology Commercialization at Ohio State; $200M+ in licensing and venture revenue.
IP and regulatory attorney (FoxKiser); former US Senate HELP Committee detailee; former USPTO patent examiner.
Former VP, Global Multiple Myeloma Franchise at Celgene; 30+ years in hematologic oncology.
Platform inventor; former Director of the Cellular Therapeutics Center at Johns Hopkins; pioneer of myeloma immunotherapy.